Cancer treatment reviews最新文献

{"title":"HER-2 directed therapies across gastrointestinal tract cancers – A new frontier","authors":"Lauren Jones,&nbsp;David Cunningham,&nbsp;Naureen Starling","doi":"10.1016/j.ctrv.2024.102789","DOIUrl":"10.1016/j.ctrv.2024.102789","url":null,"abstract":"<div><p>Gastrointestinal (GI) cancers are common and in the metastatic setting they have a poor prognosis. The current mainstay of treatment of GI cancers is chemotherapy; however, the biomarker-directed treatment landscape is evolving. HER-2 is overexpressed in a portion of GI cancers and is an emerging target for therapy, with recent FDA tumor agnostic approval for trastuzumab deruxtecan. Testing for HER-2 expression is not standardized across GI cancers, methodology requires further optimization and standardization as HER-2 targeted therapy emerges into the treatment landscape. There is established rationale for use of HER-2 targeted therapy in first line treatment of metastatic gastric cancer, and emerging evidence with variable benefit in bile duct, pancreatic and colorectal cancers.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102789"},"PeriodicalIF":9.6,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001178/pdfft?md5=c89ac52a5a59170ef4f162ff56f2eb91&pid=1-s2.0-S0305737224001178-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma","authors":"Edoardo De Simoni ,&nbsp;Francesco Spagnolo ,&nbsp;Sara Gandini ,&nbsp;Aurora Gaeta ,&nbsp;Giulio Rizzetto ,&nbsp;Elisa Molinelli ,&nbsp;Oriana Simonetti ,&nbsp;Annamaria Offidani ,&nbsp;Paola Queirolo","doi":"10.1016/j.ctrv.2024.102788","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102788","url":null,"abstract":"<div><p>In patients with resected non-metastatic melanoma, the liquid biopsy for the assessment of molecular residual disease (MRD) by circulating tumour DNA (ctDNA) represents a promising tool to stratify the risk and to monitor tumour evolution. However, its validation requires the demonstration of analytical validity, clinical validity and utility. Indeed, the development of sensitive and specific assays can optimize prognostication and eventually help clinicians to modulate adjuvant treatments, in order to improve clinical outcomes. Data about ctDNA-guided prognosis stratification is emerging, but clinical trials assessing ctDNA-guided therapeutic decisions are still ongoing. This review aims to depict the role of ctDNA-based MRD assessment in patients with non-metastatic melanoma and to provide a roadmap to face challenges for its introduction into clinical practice.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102788"},"PeriodicalIF":9.6,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141434484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","authors":"Yaowen Zhang ,&nbsp;Junru Chen ,&nbsp;Haoyang Liu ,&nbsp;Jindong Dai ,&nbsp;Junjie Zhao ,&nbsp;Sha Zhu ,&nbsp;Xingming Zhang ,&nbsp;Jiayu Liang ,&nbsp;Xu Hu ,&nbsp;Jinge Zhao ,&nbsp;Zhenhua Liu ,&nbsp;Pengfei Shen ,&nbsp;Guangxi Sun ,&nbsp;Hao Zeng","doi":"10.1016/j.ctrv.2024.102787","DOIUrl":"10.1016/j.ctrv.2024.102787","url":null,"abstract":"<div><h3>Background</h3><p>This study aimed to summarize the occurrence of immune-related adverse events (irAEs) and further evaluate their association with clinical outcomes in patients with advanced renal cell carcinoma (RCC) and urothelial carcinoma (UC) treated with immune checkpoint inhibitors (ICIs).</p></div><div><h3>Methods</h3><p>A comprehensive search of PubMed, Embase, and the Cochrane Library up to December 2023 was conducted to identify eligible studies. The details of irAEs and data regarding their correlation with clinical outcomes were extracted. R software was used for <em>meta</em>-analysis.</p></div><div><h3>Results</h3><p>A total of 27 studies involving 6148 patients with RCC or UC were included. The pooled overall incidence for any-grade and grade ≥ 3 irAEs was 44.2 % (95 % CI: 38.1 %-50.5 %) and 15.7 % (95 % CI: 11.4 %-21.1 %), respectively. Compared to those without any irAEs, patients with irAEs showed improved PFS (HR = 0.44, 95 % CI: 0.35–0.56, p &lt; 0.01) and OS (HR = 0.47, 95 % CI: 0.42–0.51, p &lt; 0.01), as well as higher ORR (OR = 3.59, 95 % CI: 3.01–4.29, p &lt; 0.01) and DCR (OR = 4.23, 95 % CI: 3.06–5.84, p &lt; 0.01). Subgroup analysis indicated that clinical outcome improvements were associated with the occurrence of irAEs, regardless of tumor type or ICI agent. Notably, patients with cutaneous irAEs, thyroid dysfunction, and grade ≤ 2 irAEs had a higher probability to achieve better survival benefits from ICI-based therapy, while pulmonary irAEs and grade ≥ 3 irAEs seemed to have a negative impact on OS. Additionally, systemic glucocorticoids administration did not affect survival outcomes.</p></div><div><h3>Conclusion</h3><p>Our findings suggest that the occurrence of irAEs could be considered as a potential prognostic factor for predicting the efficacy of ICIs in patients with advanced RCC and UC.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102787"},"PeriodicalIF":9.6,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141397989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long road towards effective HER3 targeting in breast cancer","authors":"Francesca Papa ,&nbsp;Thomas Grinda ,&nbsp;Elie Rassy ,&nbsp;Rasha Cheickh-Hussin ,&nbsp;Joana Ribeiro ,&nbsp;Lorenzo Antonuzzo ,&nbsp;Barbara Pistilli","doi":"10.1016/j.ctrv.2024.102786","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102786","url":null,"abstract":"<div><p>Breast cancer is a heterogeneous disease, encompassing multiple different subtypes. Thanks to the increasing knowledge of the diverse biological features of each subtype, most patients receive personalized treatment based on known biomarkers. However, the role of some biomarkers in breast cancer evolution is still unknown, and their potential use as a therapeutic target is still underexplored. HER3 is a member of the human epidermal growth factors receptor family, overexpressed in 50%-70% of breast cancers. HER3 plays a key role in cancer progression, metastasis development, and drug resistance across all the breast cancer subtypes. Owing to its critical role in cancer progression, many HER3-targeting therapies have been developed over the past decade with conflicting findings. Next-generation antibody-drug conjugates have recently shown promising results in solid tumors expressing HER3, including breast cancer. In this review, we discuss the HER3 role in the pathogenesis of breast cancer and its relevance across all subtypes. We also explore the new anti-HER3 treatment strategies, calling into question the significance of HER3 detection as crucial information in breast cancer treatment.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102786"},"PeriodicalIF":11.8,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001142/pdfft?md5=b2a2d0eb6a98332ad8b2340a0b01e21f&pid=1-s2.0-S0305737224001142-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141333216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes","authors":"A. Calabrese ,&nbsp;C. von Arx ,&nbsp;A.A. Tafuti ,&nbsp;M. Pensabene ,&nbsp;M. De Laurentiis","doi":"10.1016/j.ctrv.2024.102785","DOIUrl":"https://doi.org/10.1016/j.ctrv.2024.102785","url":null,"abstract":"<div><p>The detection of germline pathogenic variants (gPVs) in <em>BRCA1/2</em> and other breast cancer (BC) genes is rising exponentially thanks to the advent of multi-gene panel testing. This promising technology, coupled with the availability of specific therapies for BC BRCA-related, has increased the number of patients eligible for genetic testing. Implementing multi-gene panel testing for hereditary BC screening holds promise to maximise benefits for patients at hereditary risk of BC. These benefits range from prevention programs to antineoplastic-targeted therapies. However, the clinical management of these patients is complex and requires guidelines based on recent evidence.</p><p>Furthermore, applying multi-gene panel testing into clinical practice increases the detection of variants of uncertain significance (VUSs). This augments the complexity of patients’ clinical management, becoming an unmet need for medical oncologists.</p><p>This review aims to collect updated evidence on the most common BC-related genes besides <em>BRCA1/2</em>, from their biological role in BC development to their potential impact in tailoring prevention and treatment strategies.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102785"},"PeriodicalIF":11.8,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001130/pdfft?md5=06deac09384282c4337a3ce239ab8471&pid=1-s2.0-S0305737224001130-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141313863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of locoregional surgery in de novo stage IV breast cancer: A meta-analysis of randomized controlled trials","authors":"Wenqi Zhou ,&nbsp;Yeli Yue ,&nbsp;Jing Xiong ,&nbsp;Wei Li ,&nbsp;Xiaohua Zeng","doi":"10.1016/j.ctrv.2024.102784","DOIUrl":"10.1016/j.ctrv.2024.102784","url":null,"abstract":"<div><h3>Background</h3><p>We performed an updated <em>meta</em>-analysis to explore the value of locoregional surgery in de novo stage IV breast cancer patients.</p></div><div><h3>Methods</h3><p>A literature search was conducted to identify randomized controlled trials comparing primary tumor resection with systemic therapy in de novo stage IV breast cancer. The hazard ratio (HR) of overall survival (OS), local relapse-free survival (LRFS), and distant relapse-free survival (DRFS) were estimated and pooled.</p></div><div><h3>Results</h3><p>Six studies were eligible, including a total of 1368 patients. Both OS (HR = 0.86; 95 %CI: 0.77–0.96; p = 0.01; <em>I²</em> = 45 %) and LRFS (HR = 0.35; 95 %CI: 0.20–0.62; p = 0.0003; <em>I²</em> = 83 %) were significantly improved with locoregional surgery compared with systemic therapy alone. There was no significant difference in terms of DRFS (HR = 0.96; 95 %CI: 0.41–2.22; p = 0.92; <em>I²</em> = 86 %). The OS benefit was more pronounced in hormone receptor-positive patients (HR = 0.79; p = 0.003) and HER2-negative patients (HR = 0.80; p = 0.003).</p></div><div><h3>Conclusions</h3><p>This study demonstrated that locoregional surgery conferred significant OS and LRFS benefits in de novo stage IV breast cancer patients and may serve as an alternative choice for selected patients.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102784"},"PeriodicalIF":11.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141406427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsy: An arsenal for tumour screening and early diagnosis","authors":"Qi Zhang ,&nbsp;Xiaoli Zhang ,&nbsp;Peipei Xie ,&nbsp;Wen Zhang","doi":"10.1016/j.ctrv.2024.102774","DOIUrl":"10.1016/j.ctrv.2024.102774","url":null,"abstract":"<div><p>Cancer has become the second leading cause of death in the world, and more than 50% of cancer patients are diagnosed at an advanced stage. Early diagnosis of tumours is the key to improving patient quality of life and survival time and reducing the socioeconomic burden. However, there is still a lack of reliable early diagnosis methods in clinical practice. In recent years, liquid biopsy technology has developed rapidly. It has the advantages of noninvasiveness, easy access to sample sources, and reproducibility. It has become the main focus of research on the early diagnosis methods of tumours. This review summarises the research progress of existing liquid biopsy markers, such as circulating tumour DNA, circulating viral DNA, DNA methylation, circulating tumour cells, circulating RNA, exosomes, and tumour education platelets in early diagnosis of tumours, and analyses the current advantages and limitations of various markers, providing a direction for the application and transformation of liquid biopsy research in early diagnosis of clinical tumours.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102774"},"PeriodicalIF":11.8,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141280862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck","authors":"Ben O’Leary ,&nbsp;Heath Skinner ,&nbsp;Jonathan D Schoenfeld ,&nbsp;Lisa Licitra ,&nbsp;Christophe Le Tourneau ,&nbsp;Christina Esdar ,&nbsp;Andreas Schroeder ,&nbsp;Satu Salmio ,&nbsp;Amanda Psyrri","doi":"10.1016/j.ctrv.2024.102773","DOIUrl":"10.1016/j.ctrv.2024.102773","url":null,"abstract":"<div><p>Combinations of surgery, radiotherapy and chemotherapy can eradicate tumors in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), but a significant proportion of tumors progress, recur, or do not respond to therapy due to treatment resistance. The prognosis for these patients is poor, thus new approaches are needed to improve outcomes. Key resistance mechanisms to chemoradiotherapy (CRT) in patients with LA SCCHN are alterations to the pathways that mediate apoptosis, a form of programmed cell death. Targeting dysregulation of apoptotic pathways represents a rational therapeutic strategy in many types of cancer, with a number of proteins, including the pro-survival B-cell lymphoma 2 family and inhibitors of apoptosis proteins (IAPs), having been identified as druggable targets. This review discusses the mechanisms by which apoptosis occurs under physiological conditions, and how this process is abnormally restrained in LA SCCHN tumor cells, with treatment strategies aimed at re-enabling apoptosis in LA SCCHN also considered. In particular, the development of, and future opportunities for, IAP inhibitors in LA SCCHN are discussed, in light of recent encouraging proof-of-concept clinical trial data.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102773"},"PeriodicalIF":11.8,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141279188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies","authors":"Pablo Jiménez-Labaig ,&nbsp;Antonio Rullan ,&nbsp;Alberto Hernando-Calvo ,&nbsp;Sandra Llop ,&nbsp;Shreerang Bhide ,&nbsp;Ben O’Leary ,&nbsp;Irene Braña ,&nbsp;Kevin J. Harrington","doi":"10.1016/j.ctrv.2024.102772","DOIUrl":"10.1016/j.ctrv.2024.102772","url":null,"abstract":"<div><h3>Introduction</h3><p>There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), especially in recurrent unresectable and metastatic (R/M) setting. Antibody-drug conjugates (ADC) and bispecific antibodies (BsAb) may deliver promising results.</p></div><div><h3>Methods</h3><p>We conducted a systematic literature review to identify ADC and BsAb clinical trials, involving patients with HNSCC and NPC, from database creation to December 2023. We reported trial characteristics, overall response rate (ORR), overall survival (OS), and grade ≥ 3 treatment-related adverse events (trAEs).</p></div><div><h3>Results</h3><p>23 trials (65 % phase I) were found, involving 540 R/M patients (355 [20trials] HNSCC and 185 [5trials] NPC). There were 13 ADC (n = 343) and 10 BsAb (n = 197) trials. 96 % patients were refractory to standard of care treatments. ORR ranged from 0 to 100 %, with the highest ORR for GEN1042 plus chemoimmunotherapy. ORRs for monotherapies were 47 % for ADC, and 0–37 % for BsAb. MRG003 reached in HNSCC 43 % and NPC 47 %. BL-B01D1 54 % in NPC. Longest median OS was seen with MRG003 and KN046. Grade ≥ 3 trAEs were 28–60 % in ADC trials, and 3–33 % BsAb. Grade ≥ 3 myelosuppressive trAEs were typically seen in 8 ADC trials, while 4 BsAb showed infusion-related reactions (IRR). Four treatment-related deaths were reported (1 pneumonitis), all ADC trials.</p></div><div><h3>Conclusion</h3><p>ADC and BsAb antibodies show promise in R/M HNSCC and NPC. Results are premature by small sample sizes and lack of control arm. ADC mainly caused myelosuppression and a pneumonitis case, and BsAb IRR. Further research is warranted in this setting.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"128 ","pages":"Article 102772"},"PeriodicalIF":11.8,"publicationDate":"2024-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of BH3 mimetics in ovarian cancer","authors":"Donatella Del Bufalo ,&nbsp;Giovanna Damia","doi":"10.1016/j.ctrv.2024.102771","DOIUrl":"10.1016/j.ctrv.2024.102771","url":null,"abstract":"<div><p>Ovarian carcinoma is the leading cause of gynecological cancer-related death, still with a dismal five-year prognosis, mainly due to late diagnosis and the emergence of resistance to cytotoxic and targeted agents. Bcl-2 family proteins have a key role in apoptosis and are associated with tumor development/progression and response to therapy in different cancer types, including ovarian carcinoma. In tumors, evasion of apoptosis is a possible mechanism of resistance to therapy. BH3 mimetics are small molecules that occupy the hydrophobic pocket on pro-survival proteins, allowing the induction of apoptosis, and are currently under study as single agents and/or in combination with cytotoxic and targeted agents in solid tumors. Here, we discuss recent advances in targeting anti-apoptotic proteins of the Bcl-2 family for the treatment of ovarian cancer, focusing on BH3 mimetics, and how these approaches could potentially offer an alternative/complementary way to treat patients and overcome or delay resistance to current treatments.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"129 ","pages":"Article 102771"},"PeriodicalIF":11.8,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141142488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}